“It’s Amazing”: New Lung Cancer Treatment Shows 40% Improved Efficacy

A newly approved drug combination by the US Food & Drug Administration (FDA) offers lung cancer patients hope for longer survival. A large-scale trial, funded by Janssen Pharmaceuticals, revealed that the combination of amivantamab, a monoclonal antibody, and lazertinib, a tyrosine kinase inhibitor, can halt the progression of non-small cell lung cancer (NSCLC) for over […]

Corporate WordPress Theme By Classic Templates